Journal
CANCERS
Volume 11, Issue 6, Pages -Publisher
MDPI
DOI: 10.3390/cancers11060848
Keywords
glioblastoma; multidrug resistance; P-gp inhibitors; Src inhibitors; in vitro ADME; pharmacokinetics; brain distribution; tolerability
Categories
Funding
- Ministry of Education, Science and Technological Development, Republic of Serbia [III41031]
- AIRC (Associazione Italiana per la Ricerca sul Cancro) Grant IG-2015 [17677]
- COST Action [CM1106, CM1407]
Ask authors/readers for more resources
Overexpression of P-glycoprotein (P-gp) and other ATP-binding cassette (ABC) transporters in multidrug resistant (MDR) cancer cells is responsible for the reduction of intracellular drug accumulation, thus decreasing the efficacy of chemotherapeutics. P-gp is also found at endothelial cells' membrane of the blood-brain barrier, where it limits drug delivery to central nervous system (CNS) tumors. We have previously developed a set of pyrazolo[3,4-d]pyrimidines and their prodrugs as novel Src tyrosine kinase inhibitors (TKIs), showing a significant activity against CNS tumors in in vivo. Here we investigated the interaction of the most promising pair of drug/prodrug with P-gp at the cellular level. The tested compounds were found to increase the intracellular accumulation of Rho 123, and to enhance the efficacy of paclitaxel in P-gp overexpressing cells. Encouraging pharmacokinetics properties and tolerability in vivo were also observed. Our findings revealed a novel role of pyrazolo[3,4-d]pyrimidines which may be useful for developing a new effective therapy in MDR cancer treatment, particularly against glioblastoma.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available